Answers are grounded in this paper and cite their sources.
Preclinical pharmacokinetic study demonstrates high oral bioavailability and predominantly biliary elimination of zenarestat in rats and dogs, highlighting sustained sciatic nerve exposure.
The absorption, distribution and excretion of zenarestat have been studied in male rats and dogs after i.v. and oral administration of 14C-zenarestat. 2. The bioavailability of zenarestat was 93% in rats and 65% in dogs. A major proportion of the plasma 14C in rats and dogs was due to unchanged drug. The terminal elimination half-life of zenarestat in plasma was 6 h in rats and dogs. 3. Except for organs associated with absorption and elimination, tissue 14C levels were lower than plasma levels in rats. The distribution to, and elimination from sciatic nerve were slower than those of other tissues. 4. Most of the 14C from 14C-zenarestat administered orally and i.v. to rats and dogs was excreted in the faeces. After i.v. dosing to bile duct-cannulated rats, 96% of the radioactive dose was excreted in the bile.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: